Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome.
Barrier Function
Campylobacter
Gastrointestinal Infection
Microbiome
Serotonin
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
09
03
2018
revised:
03
07
2018
accepted:
05
07
2018
pubmed:
17
7
2018
medline:
29
1
2019
entrez:
17
7
2018
Statut:
ppublish
Résumé
The existence of postinfection irritable bowel syndrome (PI-IBS) has been substantiated by epidemiology studies conducted in diverse geographic and clinical settings. However, the available evidence has not been well summarized, and there is little guidance for diagnosis and treatment of PI-IBS. The ROME Foundation has produced a working team report to summarize the available evidence on the pathophysiology of PI-IBS and provide guidance for diagnosis and treatment, based on findings reported in the literature and clinical experience. The working team conducted an evidence-based review of publication databases for articles describing the clinical features (diagnosis), pathophysiology (intestinal sensorimotor function, microbiota, immune dysregulation, barrier dysfunction, enteroendocrine pathways, and genetics), and animal models of PI-IBS. We used a Delphi-based consensus system to create guidelines for management of PI-IBS and a developed treatment algorithm based on published findings and experiences of team members. PI-IBS develops in about 10% of patients with infectious enteritis. Risk factors include female sex, younger age, psychological distress during or before acute gastroenteritis, and severity of the acute episode. The pathogenesis of PI-PBS appears to involve changes in the intestinal microbiome as well as epithelial, serotonergic, and immune system factors. However, these mechanisms are incompletely understood. There are no evidence-based, effective pharmacologic strategies for treatment of PI-IBS. We provide a consensus-based treatment algorithm, based on clinical presentation and potential disease mechanisms. Based on a systematic review of the literature and team experience, we summarize the clinical features, pathophysiology (from animal models and human studies), and progression of PI-IBS. Based on these findings, we present an algorithm for diagnosis and treatment of PI-IBS based on team consensus. We also propose areas for future investigation.
Sections du résumé
BACKGROUND & AIMS
The existence of postinfection irritable bowel syndrome (PI-IBS) has been substantiated by epidemiology studies conducted in diverse geographic and clinical settings. However, the available evidence has not been well summarized, and there is little guidance for diagnosis and treatment of PI-IBS. The ROME Foundation has produced a working team report to summarize the available evidence on the pathophysiology of PI-IBS and provide guidance for diagnosis and treatment, based on findings reported in the literature and clinical experience.
METHODS
The working team conducted an evidence-based review of publication databases for articles describing the clinical features (diagnosis), pathophysiology (intestinal sensorimotor function, microbiota, immune dysregulation, barrier dysfunction, enteroendocrine pathways, and genetics), and animal models of PI-IBS. We used a Delphi-based consensus system to create guidelines for management of PI-IBS and a developed treatment algorithm based on published findings and experiences of team members.
RESULTS
PI-IBS develops in about 10% of patients with infectious enteritis. Risk factors include female sex, younger age, psychological distress during or before acute gastroenteritis, and severity of the acute episode. The pathogenesis of PI-PBS appears to involve changes in the intestinal microbiome as well as epithelial, serotonergic, and immune system factors. However, these mechanisms are incompletely understood. There are no evidence-based, effective pharmacologic strategies for treatment of PI-IBS. We provide a consensus-based treatment algorithm, based on clinical presentation and potential disease mechanisms.
CONCLUSIONS
Based on a systematic review of the literature and team experience, we summarize the clinical features, pathophysiology (from animal models and human studies), and progression of PI-IBS. Based on these findings, we present an algorithm for diagnosis and treatment of PI-IBS based on team consensus. We also propose areas for future investigation.
Identifiants
pubmed: 30009817
pii: S0016-5085(18)34766-8
doi: 10.1053/j.gastro.2018.07.011
pmc: PMC6309514
mid: NIHMS1500100
pii:
doi:
Types de publication
Journal Article
Practice Guideline
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
46-58.e7Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK103911
Pays : United States
Informations de copyright
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.
Références
Science. 2013 Jul 5;341(6141):1237439
pubmed: 23828941
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4554-61
pubmed: 20847294
Am J Physiol. 1989 Dec;257(6 Pt 1):G898-903
pubmed: 2692462
Aliment Pharmacol Ther. 2007 Aug 15;26(4):535-44
pubmed: 17661757
Pediatr Ann. 2014 Apr;43(4):e76-82
pubmed: 24716562
BMJ. 1997 Mar 15;314(7083):779-82
pubmed: 9080994
Am J Pathol. 2002 Apr;160(4):1529-40
pubmed: 11943737
Gastroenterology. 2002 Jun;122(7):1738-47
pubmed: 12055579
Gastroenterology. 2000 Dec;119(6):1590-9
pubmed: 11113080
Gut. 2016 Aug;65(8):1279-88
pubmed: 26071133
Environ Microbiol. 2012 Oct 15;:
pubmed: 23286720
Aliment Pharmacol Ther. 2016 Sep;44(6):576-82
pubmed: 27444134
Gastroenterol Hepatol (N Y). 2017 Nov;13(11):694-696
pubmed: 29230149
Aliment Pharmacol Ther. 2015 Jun;41(11):1029-37
pubmed: 25871571
Am J Physiol Gastrointest Liver Physiol. 2016 Apr 15;310(8):G574-85
pubmed: 26744469
Am J Physiol. 1997 Feb;272(2 Pt 1):G321-7
pubmed: 9124356
Gut. 2018 May;67(5):872-881
pubmed: 28416515
Gastroenterology. 2011 Nov;141(5):1792-801
pubmed: 21820992
Dig Dis Sci. 2009 May;54(5):937-46
pubmed: 19058006
J Neurogastroenterol Motil. 2012 Apr;18(2):200-4
pubmed: 22523730
Q J Med. 1962 Jul;31:307-22
pubmed: 13878459
World J Gastroenterol. 2010 Aug 7;16(29):3680-6
pubmed: 20677340
Am J Gastroenterol. 2018 Sep;113(9):1363-1375
pubmed: 30171215
Aliment Pharmacol Ther. 2003 Jul 1;18(1):77-84
pubmed: 12848628
Gut. 2012 Jul;61(7):997-1006
pubmed: 22180058
Aliment Pharmacol Ther. 2015 Aug;42(4):418-27
pubmed: 26104013
Yonsei Med J. 2010 Jan;51(1):45-51
pubmed: 20046513
mBio. 2014 Sep 16;5(5):e01212-14
pubmed: 25227462
Gastroenterology. 2004 Jul;127(1):179-87
pubmed: 15236184
Gut. 2016 Jan;65(1):91-9
pubmed: 25765462
Gastroenterology. 2011 Dec;141(6):2098-2108.e5
pubmed: 21856270
Aliment Pharmacol Ther. 2015 Jan;41(2):177-88
pubmed: 25348873
Gut. 2000 Dec;47(6):804-11
pubmed: 11076879
Infect Immun. 2009 Nov;77(11):5163-9
pubmed: 19687199
Neurogastroenterol Motil. 2001 Apr;13(2):155-62
pubmed: 11298994
Aliment Pharmacol Ther. 2010 Apr;31(8):883-91
pubmed: 20132151
Gastroenterology. 2014 Jul;147(1):69-77
pubmed: 24657623
Am J Gastroenterol. 2006 Jun;101(6):1288-94
pubmed: 16771951
Scand J Gastroenterol. 2014 Sep;49(9):1068-75
pubmed: 24919810
Gut. 2014 Nov;63(11):1737-45
pubmed: 24310267
Neurogastroenterol Motil. 2000 Jun;12(3):207-14
pubmed: 10867617
J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):71-8
pubmed: 16706815
Neurogastroenterol Motil. 2006 Mar;18(3):234-42
pubmed: 16487415
Gastroenterology. 2005 Jul;129(1):131-41
pubmed: 16012943
Am J Physiol Gastrointest Liver Physiol. 2001 Jul;281(1):G151-8
pubmed: 11408267
Aliment Pharmacol Ther. 2015 Feb;41(4):342-51
pubmed: 25521822
Gut. 2012 Feb;61(2):214-9
pubmed: 21911849
Gut Microbes. 2015;6(2):110-9
pubmed: 25695334
Gut. 1999 Mar;44(3):400-6
pubmed: 10026328
Neurogastroenterol Motil. 2005 Dec;17(6):863-70
pubmed: 16336502
Gastroenterology. 2017 Apr;152(5):1042-1054.e1
pubmed: 28069350
Gastroenterology. 2001 Jun;120(7):1729-36
pubmed: 11375954
Dig Dis Sci. 2011 Jul;56(7):1962-6
pubmed: 21222158
Gastroenterology. 2007 Apr;132(4):1375-87
pubmed: 17408648
Gastroenterology. 2015 Nov;149(6):1408-14
pubmed: 26255560
Nature. 2012 Sep 13;489(7415):220-30
pubmed: 22972295
Scand J Gastroenterol. 2012 Oct;47(10):1159-64
pubmed: 22783919
Neurogastroenterol Motil. 2016 May;28(5):647-58
pubmed: 26728091
Am J Physiol. 1998 Nov;275(5):G1157-65
pubmed: 9815046
Am J Gastroenterol. 2003 Jul;98(7):1578-83
pubmed: 12873581
Neurogastroenterol Motil. 2008 Oct;20(10):1110-8
pubmed: 18694443
FEMS Microbiol Rev. 2014 Sep;38(5):996-1047
pubmed: 24861948
PLoS One. 2015 May 13;10(5):e0126438
pubmed: 25970536
J Neurogastroenterol Motil. 2012 Oct;18(4):434-42
pubmed: 23106005
Gastroenterology. 1997 Oct;113(4):1224-32
pubmed: 9322517
Neurogastroenterol Motil. 2016 Oct;28(10):1561-9
pubmed: 27189227
J Physiol. 2008 Sep 15;586(18):4517-30
pubmed: 18653657
Neurogastroenterol Motil. 2011 Nov;23(11):1043-50, e499
pubmed: 21320238
Dig Dis Sci. 2008 Apr;53(4):982-9
pubmed: 17934822
Gut Microbes. 2015;6(6):364-9
pubmed: 26512631
Gut. 2004 Aug;53(8):1096-101
pubmed: 15247174
Br Med J. 1950 Feb 18;1(4650):405-9
pubmed: 15410136
Gut Pathog. 2013 Aug 30;5(1):26
pubmed: 23991642
Gastroenterology. 2006 Aug;131(2):445-50; quiz 660
pubmed: 16890598
Am J Gastroenterol. 2004 Jun;99(6):1152-9
pubmed: 15180740
Am J Gastroenterol. 2009 Feb;104(2):392-400
pubmed: 19174797
Gastroenterology. 2010 Apr;138(4):1502-13
pubmed: 20044998
Neurogastroenterol Motil. 1998 Dec;10(6):499-508
pubmed: 10050255
Am J Physiol Gastrointest Liver Physiol. 2000 Feb;278(2):G259-65
pubmed: 10666050
Lancet. 1996 Jan 20;347(8995):150-3
pubmed: 8544549
PLoS One. 2015 Sep 14;10(9):e0134836
pubmed: 26366730
Neurogastroenterol Motil. 2012 Jun;24(6):546-52, e252
pubmed: 22356614
Neurogastroenterol Motil. 2013 Jun;25(6):529-37
pubmed: 23521493
BMC Gastroenterol. 2012 Jul 20;12:91
pubmed: 22816602
J Physiol. 2006 Oct 1;576(Pt 1):257-67
pubmed: 16857712
Gastroenterology. 2003 Dec;125(6):1651-9
pubmed: 14724817
Neurogastroenterol Motil. 2008 May;20 Suppl 1:54-63
pubmed: 18402642
Aliment Pharmacol Ther. 2004 Dec;20(11-12):1317-22
pubmed: 15606393
Gastroenterology. 2016 May;150(6):1257-61
pubmed: 27147121
Gastroenterology. 2009 May;136(6):1979-88
pubmed: 19457422
J Gastroenterol. 2011 Feb;46(2):164-74
pubmed: 20848144
Gastroenterology. 2016 May;150(6):1380-92
pubmed: 27147122
Eur J Pharmacol. 1997 Oct 22;337(2-3):279-82
pubmed: 9430426
Gastroenterology. 2016 Feb 18;:
pubmed: 27144627
Gut. 2013 Jul;62(7):985-94
pubmed: 22684480
Neurogastroenterol Motil. 2014 May;26(5):696-704
pubmed: 24602083